That's exactly the point and wishful thinking on your part. You are waiting for a better price and trying to convince everyone else that this stock should be heading to your ideal reentry price of $5.70 - $6.40 bottom.
The real point is why should RPRX revisit the last low with further clinical risks removed from the excellent trial data in December.
Recent RPRX News
- Form 8-K - Current report • Edgar (US Regulatory) • 06/20/2024 12:03:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/10/2024 08:58:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/06/2024 09:06:32 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 06/04/2024 09:12:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 08:57:02 PM
- Royalty Pharma to Present at the Goldman Sachs 45th Annual Global Healthcare Conference • GlobeNewswire Inc. • 06/04/2024 08:15:00 PM
- Royalty Pharma Announces Pricing of $1.5 Billion of Senior Unsecured Notes • GlobeNewswire Inc. • 06/03/2024 09:15:27 PM
- Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses • Edgar (US Regulatory) • 06/03/2024 08:59:57 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 06/03/2024 01:13:40 PM
- Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers • Edgar (US Regulatory) • 06/03/2024 12:39:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/29/2024 09:25:01 PM
- Royalty Pharma and Agios Pharmaceuticals Enter Into Vorasidenib Royalty Agreement for $905 Million • GlobeNewswire Inc. • 05/28/2024 11:10:00 AM
- Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline • GlobeNewswire Inc. • 05/22/2024 08:10:00 PM
- Cytokinetics and Royalty Pharma Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline • GlobeNewswire Inc. • 05/22/2024 08:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/16/2024 09:42:57 PM
- Royalty Pharma to Present at Upcoming Investor Conferences • GlobeNewswire Inc. • 05/13/2024 12:15:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 01:01:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 11:17:01 AM
- Royalty Pharma Reports First Quarter 2024 Results • GlobeNewswire Inc. • 05/09/2024 11:00:00 AM
- Royalty Pharma to Acquire Royalty Interest in Sanofi’s Frexalimab • GlobeNewswire Inc. • 05/09/2024 10:45:00 AM
- Royalty Pharma to Announce First Quarter 2024 Financial Results on May 9, 2024 • GlobeNewswire Inc. • 04/19/2024 12:15:00 PM
- Royalty Pharma Declares Second Quarter 2024 Dividend • GlobeNewswire Inc. • 04/17/2024 12:15:00 PM
- Royalty Pharma to Present at TD Cowen’s 44th Annual Health Care Conference • GlobeNewswire Inc. • 02/28/2024 09:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/15/2024 02:05:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/15/2024 12:33:43 PM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM